Clinical Report: $2.2M Grant Backs Retinal Research

Overview

A University of Minnesota Medical School team has received a $2.2 million grant to study retinal diseases, focusing on age-related macular degeneration (AMD) and Doyne honeycomb retinal dystrophy. The research will explore the role of fibulin-3 in these conditions.

Background

Retinal diseases such as AMD are leading causes of vision loss. Understanding the underlying mechanisms of these diseases is crucial. The study of extracellular matrix proteins like fibulin-3 may reveal insights into disease progression.

Data Highlights

The study is supported by a four-year, $2.2 million grant from the National Eye Institute (Grant number: 2R01EY027785-07A1).

Key Findings

• The research will focus on age-related macular degeneration (AMD) and Doyne honeycomb retinal dystrophy.
• Fibulin-3, an extracellular matrix protein, is linked to several blinding eye diseases.
• The team aims to develop tools to better understand fibulin-3's role in retinal diseases.
• FDA-approved drugs will be tested for their efficacy in reducing AMD symptoms.
• The study will explore how retinal-produced extracellular matrix proteins contribute to disease.

Clinical Implications

The findings from this research may enhance understanding of fibulin-3 in retinal diseases.

Conclusion

This grant-funded research aims to unravel the complexities of retinal diseases.

Related Resources & Content

1. University of Minnesota, University of Minnesota, 2023 -- $2.2M Grant Backs Retinal Research
2. uci health — Researcher is awarded grant from BrightFocus Foundation’s National Glaucoma Research Program
3. Ophthalmology Management — Foundation Fighting Blindness and Partners to Receive Up To $46 million for Whole-Eye Transplantation Programs
4. Retinal Physician — SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
5. https://bdoc.info/dl/informationen/Guidelines-AAO.pdf
6. Japanese clinical guidelines for neovascular age-related macular degeneration | Japanese Journal of Ophthalmology | Springer Nature Link
7. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - ScienceDirect
8. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - ScienceDirect
9. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
10. NM_001039348.3(EFEMP1):c.1033C>T (p.Arg345Trp) AND Doyne honeycomb retinal dystrophy - ClinVar - NCBI
11. Checking your browser - reCAPTCHA
12. Genetic removal of Nlrp3 protects against age-related and R345W Efemp1-induced basal laminar deposit formation